Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The denosumab biosimilars Stoboclo and Osenvelt have the same indications as the reference products Prolia and Xgeva, respectively.

Clinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that ...